"ASCO 2019: Pembrolizumab Versus Placebo After First-Line Chemotherapy In Patients With Metastatic Urothelial Cancer: HCRN GU14-182"
Platinum-based chemotherapy for first-line treatment of patients with metastatic urothelial cancer is typically administered for a fixed duration followed by observation until recurrence according to researchers at the Icahn School of Medicine at Mount Sinai. However, PD-1 blockade with pembrolizumab improves survival of patients with metastatic urothelial cancer progressing despite platinum-based chemotherapy. Matthew Galsky, MD, director of genitourinary medical oncology at The Tisch Cancer Institute at Mount Sinai presented results of his phase II trial assessing maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. Dr. Galsky explained that the primary objective was to determine the progression-free survival as per irRECIST among patients treated with pembrolizumab versus placebo.
— Matthew D. Galsky, MD, Director of Genitourinary Medical Oncology at The Tisch Cancer Institute at Mount Sinai